Navigation Links
Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results
Date:4/25/2013

CHAPEL HILL, N.C., April 25, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013. The company will host a conference call and webcast at 4:30 p.m. EDT, today.

"The first quarter of 2013 was an important one for Cempra as we continued our oral solithromycin Phase 3 clinical trial in patients with community-acquired bacterial pneumonia and our Taksta Phase 2 trial in patients with prosthetic joint infections," said Prabhavathi Fernandes , Ph.D., chief executive officer of Cempra.  "Looking ahead, we continue to prepare to initiate the solithromycin intravenous-to-oral Phase 3 trial in community-acquired bacterial pneumonia, or CABP, pending available resources, and to plan meetings with the FDA on the solithromycin IV-to-oral Phase 3 trial in the second quarter and the Taksta prosthetic joint infection program later this year."

Financial ResultsQuarter ended March 31, 2013 compared to quarter ended March 31, 2012For the quarter ended March 31, 2013, Cempra reported a net loss of $10.3 million, or $0.42 per share, compared to a net loss of $3.5 million, or $0.26 per share, for the same period in 2012. 

Research and development expense in the quarter ended March 31, 2013, was $7.4 million, an increase of 293% compared to the same quarter in 2012. The higher R&D expense was primarily due to the initiation of the oral solithromycin Phase 3 clinical trial in patients with community-acquired bacterial pnuemonia and the initiation of the Taksta™ Phase 2 clinical trial in patients with prosthetic joint infections; both of which were initiated during the four
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
2. Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
3. Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
4. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
5. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
6. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
7. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
8. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
9. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
10. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
11. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 1, 2015 ... on the basis of sectors, products & services ... globally coupled with the increasing demand of advanced ... expected to propel the growth for bioinformatics market. ... information efficiently is known as bioinformatics. Decreasing cost ...
(Date:9/1/2015)... , Aug. 31, 2015 Research and ... the "Regulatory Affairs for Support Staff (London, UK ... This two day course provides an ... drug development and has been designed specifically for those ... You will gain an overview of EU regulatory procedures ...
(Date:9/1/2015)... LONDON , September 1, 2015 - ... of GARFIELD-AF R egistry data presented ... real-world insights on the evolution of ... -   The first-ever two-year ... showcased at ESC Congress 2015 expose that all-cause death was the most frequent ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... American Medical Association, individuals with type 2 diabetes that participated in a three year ... diabetes three years down the line if they elected weight loss surgery at the ...
(Date:9/1/2015)... ... , ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session of ... has taken place at Kingsborough Community College in Brooklyn in each of the past ... Calvary, and two junior counselors who were campers themselves just a few years ago. ...
(Date:9/1/2015)... ... 01, 2015 , ... Consumers overwhelmingly prefer to have their ... according to a new survey that also offers insight on why that is ... which reflects views on cosmetic medical treatments and ratings for 10 specific procedures ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in ... MonaLisa Touch® , an innovative vaginal health laser procedure that prevents and resolves ... treatment for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, Inmar ... inception more than 35 years ago. A pilot program begun by the company in ... not just those intent on pursuing careers in these fields. The program is now ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2
... By Amanda Gardner HealthDay Reporter , TUESDAY, Jan. ... moved to rescind approval of the drug Avastin to treat ... anti-cancer medication ups the odds of congestive heart failure in ... the Journal of Clinical Oncology , included almost 4,000 ...
... Researchers have produced a lasting anti-cocaine immunity in mice by ... cold virus with a particle that mimics cocaine. , ... the online edition of Molecular Therapy and funded by ... strategy might be the first to offer cocaine addicts a fairly ...
... -- Elderly people who lose their teeth may be at ... study included more than 4,000 Japanese participants, 65 and older, ... with participants who still had many of their natural teeth, ... to have experienced some memory loss or have early-stage Alzheimer,s ...
... cortical nerve cells or neurons reside in the brain,s gray ... matter, but some people with schizophrenia have a higher number ... arise in schizophrenia as a consequence of both genetic and ... has now been studied in detail in a paper by ...
... , New Rochelle, NY, January 4, 2011Lowering the body ... severe brain injury may reduce neurologic complications and improve ... injury (TBI) has been demonstrated in national studies. According ... field, when and how it is administered should depend ...
... TUCSON, Ariz. (January 4, 2011) -- Cumbersome glaucoma tests ... history thanks to a home test developed by an ... hand-held instrument involving a system of micro-force sensors, specially ... by researchers at the UA College of Engineering. The ...
Cached Medicine News:Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 2Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 3Health News:Vaccine blocks cocaine high in mice 2Health News:Vaccine blocks cocaine high in mice 3Health News:Neuronal migration errors: Right cells, wrong place 2Health News:Optimizing patient outcomes after therapeutic hypothermia for traumatic brain injury 2Health News:New glaucoma test allows earlier, more accurate detection 2
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: